Journal of Neuroimmune Pharmacology

, Volume 3, Issue 2, pp 83–94

Novel Nanomaterials for Clinical Neuroscience

  • Jamie L. Gilmore
  • Xiang Yi
  • Lingdong Quan
  • Alexander V. Kabanov
Invited Review


Neurodegenerative disorders including Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population ages. The field of nanomedicine is rapidly expanding and promises revolutionary advances to the diagnosis and treatment of devastating human diseases. This paper provides an overview of novel nanomaterials that have potential to improve diagnosis and therapy of neurodegenerative disorders. Examples include liposomes, nanoparticles, polymeric micelles, block ionomer complexes, nanogels, and dendrimers that have been tested clinically or in experimental models for delivery of drugs, genes, and imaging agents. More recently discovered nanotubes and nanofibers are evaluated as promising scaffolds for neuroregeneration. Novel experimental neuroprotective strategies also include nanomaterials, such as fullerenes, which have antioxidant properties to eliminate reactive oxygen species in the brain to mitigate oxidative stress. Novel technologies to enable these materials to cross the blood brain barrier will allow efficient systemic delivery of therapeutic and diagnostic agents to the brain. Furthermore, by combining such nanomaterials with cell-based delivery strategies, the outcomes of neurodegenerative disorders can be greatly improved.


nanomaterials neuroregeneration blood–brain barrier neuroscaffolding nanotubes/fullerenes cell-based delivery 


  1. Abidian MR, Kim, DH, Martin DC (2006) Conducting-polymer nanotubes for controlled drug release. Adv Mater 18:405–409Google Scholar
  2. Aliabadi HM, Lavasanifar A (2006) Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3:139–162PubMedGoogle Scholar
  3. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822PubMedGoogle Scholar
  4. Armstrong A, Brewer J, Newman C, Alakhov V, Pietrzynski G, Campbell S, Corrie P, Ranson M, Valle JW (2006) SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. J Clin Oncol (Meeting Abstracts) 24:4080Google Scholar
  5. Batrakova EV, Han HY, Miller DW, Kabanov AV (1998) Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res 15:1525–1532PubMedGoogle Scholar
  6. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF (2001) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 296:551–557PubMedGoogle Scholar
  7. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, Kabanov AV (2005) Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem 16:793–802PubMedGoogle Scholar
  8. Batrakova EV, Li S, Reynolds AD, Mosley RL, Bronich TK, Kabanov AV, Gendelman HE (2007) A macrophage-nanozyme delivery system for Parkinson’s disease. Bioconjug Chem 18(5):1498–1506PubMedGoogle Scholar
  9. Baxendale M (2003) Biomolecular applications of carbon nanotubes. IEE Proc Nanobiotechnol 150:3–8PubMedGoogle Scholar
  10. Blass J (2003) Cerebrometabolic abnormalities in Alzheimer’s disease. Neurol Res 25:556–566PubMedGoogle Scholar
  11. Bronich TK, Kabanov AV, Kabanov VA, Yu K, Eisenberg A (1997) Soluble complexes from poly(ethylene oxide)-block-polymethacrylate anions and N-alkylpyridinium cations. Macromolecules 30:3519–3525Google Scholar
  12. Bronich TK, Cherry T, Vinogradov SV, Eisenberg A, Kabanov VA, Kabanov AV (1998) Self-assmbly in mixtures of poly(ethylene oxide)-graft-poly(ethyleneimine) and alkyl sulfates. Langmuir 14:6101–6106Google Scholar
  13. Bronich TK, Nehls A, Eisenberg A, Kabanov VA, Kabanov AV (1999) Novel drug delivery systems based on the complexes of block ionomers and surfactants of opposite charge. Colloids Surf B 16:243–251Google Scholar
  14. Bronich TK, Popov AM, Eisenberg A, Kabanov VA, Kabanov AV (2000) Effects of block length and structure of surfactant on self-assembly and solution behavior of block ionomer complexes. Langmuir 16:481–489Google Scholar
  15. Buyukserin F, Kang M, Martin CR (2007) Plasma-etched nanopore polymer films and their use as templates to prepare “nano test tubes”. Small 3:106–110PubMedGoogle Scholar
  16. Chekhonin V, Zhirkov YA, Gurina OI, Ryabukhin IA, Lebedev SV, Kashparov IA, Dmitriyeva TB (2005) PEGylated immunoliposomes directed against brain astrocytes. Drug Deliv 12:1–6PubMedGoogle Scholar
  17. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ (2005) Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm 59:263–272PubMedGoogle Scholar
  18. D’Emanuele A, Attwood D (2005) Dendrimer–drug interactions. Adv Drug Deliv Rev 57:2147–2162PubMedGoogle Scholar
  19. Daleke DL, Hong K, Papahadjopoulos D (1990) Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1024:352–366PubMedGoogle Scholar
  20. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091PubMedGoogle Scholar
  21. de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47:323–355PubMedGoogle Scholar
  22. Ding JJ, Guo CY, Cai QL, Lin YH, Wang H (2005) In vivo expression of green fluorescent protein gene and immunogenicity of ES312 vaccine both mediated by starburst polyamidoamine dendrimers. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27:499–503PubMedGoogle Scholar
  23. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE (2006) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108:2827–2835PubMedGoogle Scholar
  24. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE (2007) Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358:148–158PubMedGoogle Scholar
  25. Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW, Lin TS (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94:9434–9439PubMedGoogle Scholar
  26. Dugan L, Lovett EG, Quick KL, Lotharius J, Lin TT, O, Malley KL (2001) Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7:243–246PubMedGoogle Scholar
  27. Ellis-Behnke RG, Liang YX, You SW, Tay DK, Zhang S, So KF, Schneider GE (2006) Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 103:5054–5059PubMedGoogle Scholar
  28. Fenoglio I, Tomatis M, Lison D, Muller J, Fonseca A, Nagy JB, Fubini B (2006) Reactivity of carbon nanotubes: Free radical generation or scavenging activity. Free Radic Biol Med 40:1227–1233PubMedGoogle Scholar
  29. Feynman RP (1960) There’s plenty of room at the bottom. Eng Sci 23:22–36Google Scholar
  30. Fortin D (2003) Altering the properties of the blood–brain barrier: disruption and permeabilization. Prog Drug Res 61:125–154PubMedGoogle Scholar
  31. Gabizon AA, Shmeeda H, Zalipsky S (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16:175–183PubMedGoogle Scholar
  32. Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, Poluektova L, Rabinow BE, Gendelman HE, Mosley RL (2006) Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol 80:1165–1174PubMedGoogle Scholar
  33. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7:1041–1053PubMedGoogle Scholar
  34. Greiner A, Wendorff JH, Yarin AL, Zussman E (2006) Biohybrid nanosystems with polymer nanofibers and nanotubes. Appl Microbiol Biotechnol 71:387–393PubMedGoogle Scholar
  35. Haensler J, Szoka FC (1993) Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconj Chem 4:372–379Google Scholar
  36. Hahn U, Gorka M, Vogtle F, Vicinelli V, Ceroni P, Maestri M, Balzani V (2002) Light-harvesting dendrimers: efficient intra- and intermolecular energy-transfer processes in a species containing 65 chromophoric groups of four different types. Angew Chem Int Ed Engl 41:3595–3598, 3514PubMedGoogle Scholar
  37. Harada A, Kataoka K (1999a) Novel polyion complex micelles entrapping enzyme molecules in the core. 2. Characterization of the micelles prepared at nonstoichiometric mixing ratios. Langmuir 15:4208–4212Google Scholar
  38. Harada A, Kataoka K (1999b) Chain length recognition: core-shell supramolecular assembly from oppositely charged block copolymers. Science 283:65–67PubMedGoogle Scholar
  39. Harada-Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K (2002) Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther 9:407–414PubMedGoogle Scholar
  40. Hartgerink J, Granja JR, Milligan RA, Ghadiri MR (1996) Self-assembling peptide nanotubes. J Am Chem Soc 118:43–50Google Scholar
  41. Hirsch A (2003) Dendrimeric fullerene derivatives, process for their preparation, and use as neuroprotectants. In: Siemens Axiva GmbH KG (DE), USAGoogle Scholar
  42. Hirsch A, Brettreich M, Wudl F (2005) Fullerenes: chemistry and reactions. In: Wiley-VCH Verlag GmbH KGaAGoogle Scholar
  43. Hou S, Wang J, Martin CR (2005a) Template-synthesized DNA nanotubes. J Am Chem Soc 127:8587–8587Google Scholar
  44. Hou S, Wang J, Martin CR (2005b) Template-synthesized protein nanotubes. Nano Lett 5:231–234PubMedGoogle Scholar
  45. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C (2007) Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Faseb J 21:1117–1125PubMedGoogle Scholar
  46. Iijima S (1991) Helical microtubules of graphitic carbon. Nature 354:56–58Google Scholar
  47. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP (2003) RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 261:43–55PubMedGoogle Scholar
  48. Jang J, Ko S, Kim Y (2006) Dual-functionalized polymer nanotubes as substrates for molecular-probe and DNA-carrier applications. Adv Funct Mater 16:154–159Google Scholar
  49. Jaturanpinyo M, Harada A, Yuan X, Kataoka K (2004) Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde. Bioconjug Chem 15:344–348PubMedGoogle Scholar
  50. Jean MJF (2003) Dendrimers and other dendritic macromolecules: From building blocks to functional assemblies in nanoscience and nanotechnology. J Polym Sci A Polym Chem 41:3713–3725Google Scholar
  51. Jin H, Chen WQ, Tang XW, Chiang LY, Yang CY, Schloss JV, Wu JY (2000) Polyhydroxylated C(60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J Neurosci Res 62:600–607PubMedGoogle Scholar
  52. Junghans M, Loitsch SM, Steiniger SC, Kreuter J, Zimmer A (2005) Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur J Pharm Biopharm 60:287–294PubMedGoogle Scholar
  53. Kabanov AV, Alakhov VY (2002) Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19:1–72PubMedGoogle Scholar
  54. Kabanov AV, Gendelman HE (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 32:1054–1082PubMedGoogle Scholar
  55. Kabanov A, Chekhonin VP, Alakhov VYu, Batrakova EV, Lebedev AS, Melik-Mubarov NS, Arzhakov SA, Levashov AV, Morozov GV, Severin ES et al (1989) The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett 258:343–345PubMedGoogle Scholar
  56. Kabanov AV, Vinogradov SV, Suzdaltseva YG, Alakhov V (1995) Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem 6:639–643PubMedGoogle Scholar
  57. Kadiu I, Glanzer JG, Kipnis J, Gendelman HE, Thomas MP (2005) Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox Res 8:25–50PubMedGoogle Scholar
  58. Kataoka K, Harada A, Nagasaki Y (2001) Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47:113–131PubMedGoogle Scholar
  59. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716PubMedGoogle Scholar
  60. Kitchens KM, El-Sayed ME, Ghandehari H (2005) Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev 57:2163–2176PubMedGoogle Scholar
  61. Kokovay E, Cunningham LA (2005) Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson’s disease. Neurobiol Dis 19:471–478PubMedGoogle Scholar
  62. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409–416PubMedGoogle Scholar
  63. Kroto HW, Heath JR, O, Brien SC, Curl RF, Smalley RE (1985) C60: buckminsterfullerene. Nature 318:162–163Google Scholar
  64. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999a) MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson’s disease. Acta Neurobiol Exp (Wars) 59:1–8Google Scholar
  65. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999b) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50–61PubMedGoogle Scholar
  66. Kwon GS (2003) Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20:357–403PubMedGoogle Scholar
  67. Lacerda L, Bianco A, Prato M, Kostarelos K (2006) Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 58:1460–1470PubMedGoogle Scholar
  68. Lawson LJ, Perry VH, Gordon S (1992) Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48:405–415PubMedGoogle Scholar
  69. Liang Z, Susha AS, Yu A, Caruso F (2003) Nanotubes prepared by layer-by-layer coating of porous membrane templates. Adv Mater 15:1849–1853Google Scholar
  70. Liu M, Kono K, Frechet JM (2000) Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release 65:121–131PubMedGoogle Scholar
  71. Lockman P, Mumper RJ, Khan MA, Allen DD (2002) Nanoparticle technology for drug delivery across the blood brain barrier. Drug Dev Ind Pharm 28:1–13PubMedGoogle Scholar
  72. Lovat V, Pantarotto D, Lagostena L, Cacciari B, Grandolfo M, Righi M, Spalluto G, Prato M, Ballerini L (2005) Carbon nanotube substrates boost neuronal electrical signaling. Nano Lett 5:1107–1110PubMedGoogle Scholar
  73. Male D, Rezaie P (2001) Colonisation of the human central nervous system by microglia: the roles of chemokines and vascular adhesion molecules. Prog Brain Res 132:81–93PubMedCrossRefGoogle Scholar
  74. Martin C (1994) Nanomaterials: a membrane-Based synthetic approach. Science 266:1961–1966PubMedGoogle Scholar
  75. Martin CR, Kohli P (2003) The emerging field of nanotube biotechnology. Nat Rev Drug Discov 2:29–37PubMedGoogle Scholar
  76. Matsumoto K, Sato C, Naka Y, Kitazawa A, Whitby RL, Shimizu N (2007) Neurite outgrowths of neurons with neurotrophin-coated carbon nanotubes. J Biosci Bioeng 103:216–220PubMedGoogle Scholar
  77. Matsumura Y (2006) Micelle carrier system in clinical trial. Nippon Rinsho 64:316–321PubMedGoogle Scholar
  78. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775–1781PubMedGoogle Scholar
  79. Maurer N, Fenske DB, Cullis PR (2001) Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1:923–947PubMedGoogle Scholar
  80. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81–104PubMedGoogle Scholar
  81. Metodiewa D, Koska C (2000) Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 1:197–233PubMedCrossRefGoogle Scholar
  82. Nguyen HK, Lemieux P, Vinogradov SV, Gebhart CL, Guerin N, Paradis G, Bronich TK, Alakhov VY, Kabanov AV (2000) Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther 7:126–138PubMedGoogle Scholar
  83. Oberdorster E (2004) Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 112:1058–1062PubMedCrossRefGoogle Scholar
  84. Oberlin A, Endo M, Koyama T (1976) Filamentous growth of carbon through benzene decomposition. J Cryst Growth 32:335–349Google Scholar
  85. Oh KT, Bronich TK, Bromberg L, Hatton TA, Kabanov AV (2006) Block ionomer complexes as prospective nanocontainers for drug delivery. J Control Release 115:9–17PubMedGoogle Scholar
  86. Pardridge W (1999) Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev 36:299–321PubMedGoogle Scholar
  87. Pulskamp K, Diabate S, Krug HF (2007) Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. Toxicol Lett 168:58–74PubMedGoogle Scholar
  88. Raja P, Connolley J, Ganesan GP, Ci L, Ajayan PM, Nalamasu O, Thompson DM (2007) Impact of carbon nanotube exposure, dosage and aggregation on smooth muscle cells. Toxicol Lett 169:51–63PubMedGoogle Scholar
  89. Richardson-Burns S, Hendricks JL, Foster B, Povlich LK, Kim DH, Martin DC (2007) Polymerization of the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) around living neural cells. Biomaterials 28:1539–1552PubMedGoogle Scholar
  90. Roy S, Zhang K, Roth T, Vinogradov S, Kao RS, Kabanov A (1999) Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat Biotechnol 17:476–479PubMedGoogle Scholar
  91. Sayes C, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, Moore VC, Doyle CD, West JL, Billups WE, Ausman KD, Colvin VL (2006) Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett 161:135–142PubMedGoogle Scholar
  92. Schubert D, Dargusch R, Raitano J, Chan SW (2006) Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun 342:86–91PubMedGoogle Scholar
  93. Shaw L, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007) Biomarkers of neurodegenertion for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6:295–303PubMedGoogle Scholar
  94. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM (2001) Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 98:12754–12759PubMedGoogle Scholar
  95. Silva GA (2005) Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol 63:301–306PubMedGoogle Scholar
  96. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI (2004) Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303:1352–1355PubMedGoogle Scholar
  97. Simard AR, Rivest S (2004) Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. Faseb J 18:998–1000PubMedGoogle Scholar
  98. Solomatin SV, Bronich TK, Kabanov VA, Eisenberg A, Kabanov AV (2003) Environmentally responsive nanoparticles from block ionomer complexes: effect of pH and ionic strength. Langmuir 19:8069–8076Google Scholar
  99. Solomatin SV, Bronich TK, Eisenberg A, Kabanov VA, Kabanov AV (2004) Colloidal stability of aqueous dispersions of block ionomer complexes: effects of temperature and salt. Langmuir 20:2066–2068PubMedGoogle Scholar
  100. Solomatin SV, Bronich TK, Eisenberg A, Kabanov VA, Kabanov AV (2007) Nanomaterials from ionic block copolymers and single-, double-, and triple-tail surfactants. Langmuir 23:2838–2842PubMedGoogle Scholar
  101. Streit WJ, Walter SA, Pennell NA (1999) Reactive microgliosis. Prog Neurobiol 57:563–581PubMedGoogle Scholar
  102. Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 57:2106–2129PubMedGoogle Scholar
  103. Tian Y, He Q, Cui Y, Li J (2006) Fabrication of protein nanotubes based on layer-by-layer assembly. Biomacromolecules 7:2539–2542PubMedGoogle Scholar
  104. Torchilin VP (2002) PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev 54:235–252PubMedGoogle Scholar
  105. Torchilin VP (2004) Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61:2549–2559PubMedGoogle Scholar
  106. Tsai CJ, Zheng J, Aleman C, Nussinov R (2006) Structure by design: from single proteins and their building blocks to nanostructures. Trends Biotechnol 24:449–454PubMedGoogle Scholar
  107. Vinogradov SV (2006) Colloidal microgels in drug delivery applications. Curr Pharm Des 12:4703–4712PubMedGoogle Scholar
  108. Vinogradov SV, Bronich TK, Kabanov AV (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 54:135–147PubMedGoogle Scholar
  109. Vinogradov S, Batrakova EV, Kabanov AV (2004) Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 15:50–60PubMedGoogle Scholar
  110. Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J (2005) Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug Chem 16:397–405PubMedGoogle Scholar
  111. Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K (2006) Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 5:52–59PubMedGoogle Scholar
  112. Xiao R, Cho SI, Liu R, Lee SB (2007) Controlled electrochemical synthesis of conductive polymer nanotube structures. J Am Chem Soc 129:4483–4489PubMedGoogle Scholar
  113. Yan X, He Q, Wang K, Duan L, Cui Y, Li J (2007) Transition of cationic dipeptide nanotubes into vesicles and oligonucleotide delivery. Angew Chem Int Ed Engl 46:2431–2434PubMedGoogle Scholar
  114. Yang H, Kao WJ (2006) Dendrimers for pharmaceutical and biomedical applications. J Biomater Sci Polym Ed 17:3–19PubMedGoogle Scholar
  115. Yang F, Murugan R, Ramakrishna S, Wang X, Ma YX, Wang S (2004) Fabrication of nano-structured porous PLLA scaffold intended for nerve tissue engineering. Biomaterials 25:1891–1900PubMedGoogle Scholar
  116. Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ (2006) Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12:3792–3802PubMedGoogle Scholar
  117. Yuwono VM, Hartgerink JD (2007) Peptide amphiphile nanofibers template and catalyze silica nanotube formation. Langmuir 23:5033–5038PubMedGoogle Scholar
  118. Zhang GD, Harada A, Nishiyama N, Jiang DL, Koyama H, Aida T, Kataoka K (2003) Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release 93:141–150PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jamie L. Gilmore
    • 2
  • Xiang Yi
    • 1
  • Lingdong Quan
    • 2
  • Alexander V. Kabanov
    • 1
  1. 1.Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of PharmacyUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Department of Pharmaceutical Sciences, College of PharmacyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations